Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019 May 14;365:l2006. doi: 10.1136/bmj.l2006. PubMed PMID: 31088853.
Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017 Mar;27(3):315-389. doi: 10.1089/thy.2016.0457. Erratum in: Thyroid. 2017 Sep;27(9):1212. PubMed PMID: 28056690.
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421. Erratum in: Thyroid. 2017 Nov;27(11):1462. PubMed PMID: 27521067.
Gharib H, Papini E, Garber JR, et al; AACE/ACE/AME Task Force on Thyroid Nodules. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE. Endocr Pract. 2016 May;22(5):622-39. doi: 10.4158/EP161208.GL. PubMed PMID: 27167915.
Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751. doi: 10.1089/thy.2014.0028. PubMed PMID: 25266247; PubMed Central PMCID: PMC4267409.
Garber JR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012 Nov-Dec;18(6):988-1028. Erratum in: Endocr Pract. 2013 Jan-Feb;19(1):175. PubMed PMID: 23246686.
American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009 Jun;19(6):565-612. doi: 10.1089/thy.2008.0403. Review. Erratum in: Thyroid. 2009 Nov;19(11):1295. PubMed PMID: 19469690.
Elsheikh TM. Diagnostic Terminology and Criteria for the Cytologic Diagnosis of Thyroid Lesions. Papanicolaou Society of Cytopathology Guidelines. http://www.papsociety.org/guidelines.html. Accessed June 21, 2019.
Definition, Etiology, PathogenesisTop
Subacute painful thyroiditis (de Quervain thyroiditis, granulocytic thyroiditis, subacute granulomatous thyroiditis, giant cell thyroiditis) is probably of viral origin and typically follows a 4-phase course. There is a strong correlation of subacute thyroiditis with the presence of human leukocyte antigen (HLA)-B35. The disease is usually preceded (2-8 weeks earlier) by an upper respiratory tract infection.
Clinical Features and Natural HistoryTop
The disease can be divided into 4 distinct phases (see Table 1). Initially the dominant features are painful swelling of the thyroid gland and fever; pain is referred to the ears, mandibular angle, throat, and upper chest, and it is accompanied by exquisite tenderness of the thyroid gland. Thyrotoxicosis (lasting 2-8 weeks) results from destruction of the glandular parenchyma and release of thyroid hormones. Fatigue, malaise, anorexia, and muscle pain are common. The pain and fever subside spontaneously and hormone levels normalize after 8 to 16 weeks. Phase 3 (hypothyroidism) is not always present. Permanent hypothyroidism is rare and recovery is almost always complete (phase 4). A rapidly growing nodule, requiring cytologic assessment to exclude malignancy, may actually be an inflammatory infiltrate in the course of subacute thyroiditis. In ~2% of patients the disease may recur after a long remission (up to 20 years).
DiagnosisTop
1. Laboratory tests:
1) Extremely elevated erythrocyte sedimentation rate (ESR), usually >50 mm/h, and C-reactive protein (CRP) are common.
2) Thyroid-stimulating hormone (TSH) and thyroid hormones: see Table 1.
3) Antithyroid antibodies are uncommonly present; thyroglobulin (Tg) antibodies are more frequent than thyroperoxidase (TPO) antibodies.
2. Imaging studies: Thyroid ultrasonography reveals diffuse or focal hypoechogenicity of the thyroid gland and it is uncommonly needed for the diagnosis. Radionuclide thyroid imaging shows a very low iodine uptake, usually <1% to 3% (in the early phase of the disease).
3. Cytology (fine-needle aspiration biopsy): Rarely needed. The dominant cells are neutrophils, giant cells (characteristic polynuclear macrophages), and epithelioid cells (mononuclear macrophages).
The key diagnostic criteria are a painful or tender goiter; elevated ESR, CRP, or both; transient thyrotoxicosis; and significantly decreased iodine uptake.
1. Acute infectious thyroiditis with abscess formation.
2. Other rare types of granulomatous thyroiditis: tuberculous thyroiditis, fungal thyroiditis (Aspergillus, Candida, Cryptococcus); Pneumocystis jiroveci thyroiditis in immunodeficient patients.
3. Traumatic thyroiditis.
4. Radiation thyroiditis.
5. Acute hemorrhagic nodule.
6. If pain is not a dominant feature, differential diagnosis should include painless (“silent”) thyroiditis and other forms of thyrotoxicosis (see Thyroiditis; see Thyrotoxicosis and Hyperthyroidism).
TreatmentTop
The hyperthyroid phase requires no antithyroid treatment, as it is not caused by excess thyroid hormone synthesis. Beta-blockers, such as propranolol, bisoprolol, or metoprolol, may be used in patients with bothersome symptoms of hyperthyroidism.
Administer acetylsalicylic acid 2 to 4 g/d or nonsteroidal anti-inflammatory drugs to control pain and inflammation if not contraindicated; if pain is severe, consider prednisone 40 to 60 mg/d for 1 to 2 weeks, then taper the dose down to discontinue treatment in ≤4 weeks. The use of glucocorticoids does not lower the probability of transient hypothyroidism, but it decreases and shortens discomfort.
In the hypothyroid phase consider levothyroxine (L-T4) replacement therapy in those with a TSH level >10 mIU/L, significant symptoms, or both; note that hypothyroidism is usually transient and therapy should not be continued indefinitely. Replacement therapy may be withheld after 6 to 8 weeks with a follow-up of thyroid function tests to be sure that hypothyroidism is not permanent. There is no indication for surgery, as the disease is self-limiting and does not cause permanent thyroid damage.
TablesTop
Hormone levels |
Iodine uptake |
Clinical features | |
Phase 1 |
↑ FT4, ↑ FT3, ↓ TSH |
Low |
Thyrotoxicosis |
Phase 2 |
Normal |
Low |
Euthyroidism |
Phase 3 |
↓ FT4, ↓ FT3, ↑ TSH |
High |
Hypothyroidism |
Phase 4 |
Normal |
Normal |
Euthyroidism |
↑, increase; ↓, decrease; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone. |